Abstracts based on a societal perspective, was assessed for women with menopausal symptoms. METHODS: An individual state transition model populated Swedish data was used to estimate the cost-effectiveness of women with menopausal symptoms. The model consists of the following disease states: Coronary Heart Disease (CHD), Stroke, Venous thromboembolic events (VTE), breast cancer, colorectal cancer, hip fracture, vertebral fracture and wrist fracture. HRT therapy was modelled by its impact on the disease risks during therapy and possible effects after the cessation of therapy. The model calculates costs and health effects or quality adjusted life years (QALYs) with and without intervention. The resulting cost per gained QALY was compared to the value of a gained QALY, which was set to 65,000€. RESULTS: The cost per QALY gained for Swedish women with intact uterus and menopausal symptoms were estimated to 1404€, 1188€, and 1004€ when the therapy started at the age of 50, 55, and 60, respectively. The cost per QALY gained was found to be below the set value of a QALY at very low symptom related reductions in the quality of life. CONCLUSIONS: The results indicate that there is high probability that HRT is cost-effective for the treatment of women with menopausal symptoms. Oxford University, Oxford, Oxfordshire, UK; 2 Oxford University, UK OBJECTIVE: Stroke is a major cause of morbidity, health service use, and death in the UK. Previous studies report substantial associated costs, particularly related to hospitalisation. However, no previous UK analysis has used data from a population-based incidence study with full case ascertainment, without which major inclusion bias is likely. Using data from such a study, we estimate the acute costs per patient over the first year from initial stroke, by severity of stroke and prior atrial fibrillation. METHODS: Event and hospitalisation (inpatient or outpatient) data were obtained from the Oxford Vascular Study, a prospective cohort study of all individuals in 9 general practices in Oxfordshire, UK, which identified 346 patients experiencing a stroke from April 1, 2002-March 31, 2004. Transient ischaemic attacks were excluded. Mean costs per patient were calculated, adjusting for censoring. RESULTS: In all, 212 (62%) patients were admitted, the remainder being managed in the outpatient clinic. The mean censoring-adjusted cost per patient was GBP6508, 69% of which was incurred within 60 days after the index event. Patients with stroke recurrence in the study period incurred costs of £7881 compared to GBP6089 in those without. Costs in patients with prior atrial fibrillation were £9757, compared with £5687 in those without (p = 0.028). Patient costs by stroke severity (28-day Rankin score 0/1 = mild, 2/3 = moderate, 4/5 = severe, 6 = dead) were £1138, £7471, £18181, and £1602. CONCLUSIONS: We derived reliable and up-to-date estimates of acute care costs associated with stroke over the first 12 months, using data from an "ideal" population-based incidence study. The impact of severity of initial stroke and of prior atrial fibrillation on subsequent costs. Our estimates, which will be extended as follow-up continues, should be of value to analysts interested in assessing the burden of stroke and the costeffectiveness of interventions.
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PCV24 PHARMACOECONOMIC EVALUATION OF THE CIBIS-II TRIAL
Di Stasi F, Scalone L, Mantovani LG University of Milan, Milan, Italy OBJECTIVES: Beta-blockers have provided evidence of improving survival in chronic heart failure (CHF) patients. Specifically, the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) has demonstrated a significant reduction in mortality and morbidity among patients with moderate to severe CHF treated with bisoprolol. Our aim was to investigate the economic consequence of bisoprolol therapy in CHF patients in Italy. METHODS: Data were derived from the CIBIS-II trial. We conducted a costeffectiveness analysis, comparing standard care + bisoprolol vs standard care + placebo in the perspective of the Italian National Health Service (NHS). We identified and quantified medical costs: drug costs according to the Italian market price; specialist visits for initiation and up-titration of bisoprolol therapy and hospitalizations were quantified on the basis of the NHS tariffs (2004) . Effects were measured in terms of mortality and morbidity reduction (number of deaths, life years saved and frequency of hospitalizations). We considered an observational period of 1.3 years that was the average follow-up recorded in the trial. Discounting was not performed because of the relatively short follow-up of patients. We conducted one-way sensitivity analyses on unit cost and effectiveness. RESULTS: The overall cost of care per 1000 patients treated for 1.3 years was estimated in 2,043,700€ in the bisoprolol group and in 2,366,168€ in the placebo group, resulting in a net saving of 322,468€. The number of additional patients alive with bisoprolol was 55 per 1000 patients, the number of LYS was 36 at 1.3 year. CON-CLUSION: Bisoprolol therapy is dominant since it is both less costly and more effective than standard care. Results of sensitivity analysis showed that bisoprolol therapy remains dominant even to changes in unit cost of drug, hospitalizations and frequency of hospital admissions.
PCV25 SMOKING CESSATION FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A COST-EFFECTIVENESS ANALYSIS
Der Kinderen AJ, Franco OH, De Laet C Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands OBJECTIVES: The effectiveness of smoking cessation (SC) in the reduction of cardiovascular disease (CVD) risk is demonstrated. However, different options exist with variable levels of costs and effects and which one to choose for primary prevention of CVD is unclear. We evaluated the cost-effectiveness of different strategies of SC. METHODS: Using data from the Framingham Heart Study and the Framingham Offspring Study we built multistate life tables to model the cost-effectiveness of different SC therapies (Nurse or GP advice, nicotine substitutes (with or without GP guidance), buproprion and a combination of buproprion and nicotine substitutes) in male smokers free of CVD at baseline and aged between 45 and 65. Participants were categorized in terms of 10 years absolute risk of coronary heart disease (based on the Anderson Formulae) and age. Cessation rates, risk reduction rates for CVD and relapse rates were taken from the literature. We calculated the cost-effectiveness in terms of costs per year of life saved (LYS) using a time horizon of 5 and 10 years. A thirdparty payer perspective was used and cost and effects were discounted at 4%. Costs were estimated either by tariffs or market prices and costs of prevented events were taken from the literature. Finally, we compared the strategies in an (incremental) costeffectiveness analysis. RESULTS: Costs per LYS for all strategies were negative at all levels of risk and age groups. SC with GP advice was most favourable, ranging from -4919€ to -3187€ and SC with buproprion the least (-3460€, -1215€). In the incremental analysis SC with nicotine substitutes alone is to be
